Merck CEO Frazier on Immunotherapy, Drug Pricing

Ken Frazier, chairman and chief executive officer at Merck, explains the company's work on immune-oncology treatment for cancer patients, the amount of R&D money it takes to bring a new medicine to market, drug pricing and health care costs, and the battle against Alzheimer's disease, and the need for acquisitions. He speaks with Bloomberg's David Westin on "Bloomberg ‹GO›." (Source: Bloomberg)

Full Show: Surveillance (07/27)
28:48 - Bloomberg Surveillance hosted by Tom Keene and Francine Lacqua. Guests include Andrew Bailey, chief executive officer at Financial Conduct Authority, Severin Schwan, chief executive officer at Roche Holding AG, and Richard Clarida, global strategic adviser at Pimco. (Source: Bloomberg)
  • Roche CEO Schwan on Profit Forecast, Drug Pipeline
  • Full Show: Bloomberg Daybreak: Americas (07/25)
  • Full Show: Surveillance (07/25)